Ekso Bionics partners with MediTouch to distribute the BalanceTutor rehabilitation system in the U.S., enhancing patient care.
Quiver AI Summary
Ekso Bionics Holdings, Inc. has announced a partnership with MediTouch Inc. to exclusively distribute MediTouch's BalanceTutor™ rehabilitation system in the United States. The BalanceTutor features a unique 4D perturbation treadmill designed to help patients with balance impairments respond safely to unexpected disturbances while walking. The system supports patient weight through an overhead frame, promoting safety during rehabilitation. Ekso Bionics' CEO, Scott Davis, expressed enthusiasm about integrating BalanceTutor into their offerings to enhance patient care and increase market reach. MediTouch's VP, Moshe Druker, highlighted the partnership as a significant opportunity to expand access to their innovative technology for improving balance and independence in individuals undergoing rehabilitation.
Potential Positives
- Ekso Bionics has become the exclusive authorized sales agent and distributor of MediTouch's BalanceTutor rehabilitation system in the United States, enhancing its market position.
- The BalanceTutor employs advanced technology that complements Ekso Bionics’ existing offerings, potentially increasing sales opportunities and customer engagement in the rehabilitation space.
- This partnership signifies a strategic collaboration that can lead to greater awareness and adoption of innovative rehabilitation technologies across physical therapy facilities in the U.S.
- The introduction of the BalanceTutor aligns with Ekso Bionics’ mission to improve health and quality of life through innovative technology, strengthening its brand identity in the medical technology sector.
Potential Negatives
- The press release includes a significant forward-looking statement warning of risks and uncertainties that could impact the company's ability to successfully distribute the BalanceTutor, raising concerns about potential execution challenges.
- The mention of "the Company's inability to obtain adequate financing" indicates financial vulnerabilities that could impede growth and operational stability.
- The potential risks stated regarding product liability, recall, and warranty claims suggest issues that could damage the company's reputation and financial health.
FAQ
What is the BalanceTutor rehabilitation system?
The BalanceTutor is a patented rehabilitation system using a 4D treadmill to enhance balance reactions in patients.
How will Ekso Bionics distribute the BalanceTutor?
Ekso Bionics has entered an exclusive agreement to serve as the sales agent and distributor for the BalanceTutor in the U.S.
What are the benefits of using the BalanceTutor?
The BalanceTutor helps patients improve their balance and reaction to disturbances, promoting safety during rehabilitation.
Who is MediTouch and what do they specialize in?
MediTouch is an Israeli company focused on innovative physical rehabilitation solutions for medical centers and clinics.
What is the goal of the partnership between Ekso Bionics and MediTouch?
The partnership aims to increase access to BalanceTutor technology for rehabilitation facilities across the United States.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$EKSO Insider Trading Activity
$EKSO insiders have traded $EKSO stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $EKSO stock by insiders over the last 6 months:
- SCOTT G. DAVIS (CEO) sold 23,315 shares for an estimated $111,912
- JEROME WONG (Chief Financial Officer) sold 11,288 shares for an estimated $54,182
- JASON C JONES (Chief Operating Officer) sold 9,723 shares for an estimated $46,670
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$EKSO Hedge Fund Activity
We have seen 12 institutional investors add shares of $EKSO stock to their portfolio, and 21 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STATE STREET CORP removed 138,580 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $455,928
- ARMISTICE CAPITAL, LLC removed 136,159 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $447,963
- RENAISSANCE TECHNOLOGIES LLC removed 82,116 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $270,161
- CONSOLIDATED PORTFOLIO REVIEW CORP added 64,883 shares (+inf%) to their portfolio in Q3 2025, for an estimated $332,849
- FNY INVESTMENT ADVISERS, LLC removed 52,500 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $172,725
- CITADEL ADVISORS LLC added 38,551 shares (+inf%) to their portfolio in Q3 2025, for an estimated $197,766
- UBS GROUP AG added 32,456 shares (+540933.3%) to their portfolio in Q3 2025, for an estimated $166,499
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$EKSO Analyst Ratings
Wall Street analysts have issued reports on $EKSO in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/18/2025
- Lake Street issued a "Buy" rating on 07/29/2025
To track analyst ratings and price targets for $EKSO, check out Quiver Quantitative's $EKSO forecast page.
$EKSO Price Targets
Multiple analysts have issued price targets for $EKSO recently. We have seen 2 analysts offer price targets for $EKSO in the last 6 months, with a median target of $7.75.
Here are some recent targets:
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $6.0 on 11/18/2025
- Ben Haynor from Lake Street set a target price of $9.5 on 07/29/2025
Full Release
SAN RAFAEL, Calif. and TNUVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has entered into an agreement with Israel-based MediTouch Inc. (“MediTouch”) to become the exclusive authorized sales agent and distributor of MediTouch’s BalanceTutor™ rehabilitation system in the United States.
The BalanceTutor is the only known rehabilitation system that employs an advanced 4D perturbation patented treadmill and multiple force and movement sensors which allow patients impacted by impaired balance to react to unanticipated disturbances while walking. The BalanceTutor 4D treadmill can move forward, backward, and side-to-side while a patient is standing still or walking to elicit a slip, trip, or stumble. Patient weight is supported by an overhead frame that is designed to promote safe responses to disturbances of balance without the patient risk of experiencing a fall. The BalanceTutor’s proprietary 4D perturbations mimic realistic balance challenges that require a reactive response while maintaining patient and physical therapist safety.
“We are excited to add MediTouch’s BalanceTutor rehabilitation system to our leading technology offerings, expanding our reach in patient care,” commented Ekso Bionics’ Chief Executive Officer, Scott Davis. “We believe the BalanceTutor is synergistic with our current go-to-market strategy by leveraging a common customer call point with a technology that is complementary to our current enterprise health exoskeleton solutions. We look forward to working with MediTouch to help ensure that the groundbreaking BalanceTutor gains awareness, acceptance and adoption by inpatient and outpatient physical rehabilitation facilities across the country.”
“We are thrilled to partner with Ekso Bionics to grow the presence of the BalanceTutor across the U.S.,” said Moshe Druker, VP of Global Business Development at MediTouch. “This collaboration marks an important milestone for MediTouch, enabling us to expand access to our innovative rehabilitation technology and help more individuals regain balance, confidence, and independence.”
About Ekso Bionics
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance, and mobility across medical and industrial applications. Based upon its industry-leading expertise, the Company focuses on improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human function. Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol "EKSO." For more information, visit: www.eksobionics.com .
About MediTouch
MediTouch is dedicated to developing and delivering innovative physical rehabilitation solutions for medical centers, outpatient clinics, and home healthcare settings. Our technologies empower clinicians and patients with advanced tools that support effective, engaging, and measurable rehabilitation.
For more information, visit: www.meditouch.co.il.
Forward-Looking Statements
Any statement contained in this press release that does not describe historical facts may constitute a forward-looking statement. Forward-looking statements may include, without limitation, statements regarding the ability of the Company to distribute the BalanceTutor rehabilitation system in the United States, the potential impacts of the Company’s devices to patients using the devices, and the Company’s ability to bolster demand for its products and execute on its long-term growth strategy. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund and grow the Company's operations and to develop or enhance the Company’s technology, the Company’s failure to successfully incorporate the BalanceTutor into its sales strategy on a timely basis or at all, or risks related to product liability, recall and warranty claims. These and other factors are identified and described in more detail in the Company’s filings with the U.S. Securities and Exchange Commission. To learn more about Ekso Bionics please visit the Company’s website at www.eksobionics.com or follow @EksoBionics on X. The Company does not undertake to update these forward-looking statements, except as required by law.
Contact:
Ekso Bionics
Stephen Kilmer
Investor Relations
(646) 274-3580
[email protected]